Navigation Links
BioDrain Announces First Quarter 2013 Results

MINNEAPOLIS, May 15, 2013 /PRNewswire/ -- BioDrain Medical, Inc. (OTCQB: BIOR) (the "Company"), producer of the FDA approved STREAMWAY System for automated, direct-to-drain surgical fluid disposal that reduces the risk of exposure to hazardous waste, today reported its results for the first quarter ended March 31, 2013.

Key Highlights:

  • Revenues of $127,727 for Q1 2013 were up over 450% compared to Q1 2012
  • Sales to operating rooms, surgical centers and hospital systems in new geographies have expanded BioDrain's presence in the surgical waste fluid management industry
  • Purchase order and trial unit for the first quarter exceed 20 STREAMWAY Systems
  • Revenues for the first quarter of 2013 were $127,727, up over 450% compared to $22,635 for the same period in 2012. Gross profit for the first quarter of 2013 was $86,123, nearly a 10-fold increase from $8,829 for the same period in 2012.

    Net loss for the period was ($2.1) million, or ($0.02) per diluted share, compared to net loss of ($713,367), or ($0.02) per diluted share, in the comparable period in 2012. The increased loss resulted in part from increased stock compensation costs due to stock option valuations for the first quarter, as well as an increase in investor stock compensation, a method of remuneration to an investor in lieu of cash equity financing raised as the Company ramps up production to meet second and third quarter demand. BioDrain CEO, Josh Kornberg , emphasized, "We have proposed additional small financing to allow us to further our production capability to meet market demand."

    Mr. Kornberg continued, "BioDrain had a great first quarter in 2013. Not only do we have a robust new business pipeline that includes numerous hospital networks and surgical centers, but in the past several weeks we have added new installations and expanded our presence in the Northeast and Mid-Atlantic regions, which are now primed for future growth.  Thanks to a successful sales quarter, we are continuing to see increased interest from facilities across the U.S. and have drawn major interest from international medical equipment distributors, which could add significantly to the Company's sales force."

    He concluded, "We are experiencing significant momentum as the market becomes educated and continues to demand the safest and most effective waste management systems. On the heels of a great first quarter, we look forward to continuing the conversion of successful trials into sales and leveraging our relationships and existing installations to make further headway into the market. We believe this momentum will continue throughout the rest of 2013 and beyond."

    About BioDrain Medical
    BioDrain Medical, Inc. has a fully automated, patented, FDA cleared, surgical fluid disposal system that virtually eliminates certain operating room workers' exposure to blood, irrigation fluid and other potentially infectious fluids found in the surgical environment. Today's manual surgical fluid handling methods of hand-carrying filled surgical fluid canisters and emptying these canisters is an exposure risk and an antiquated approach to the handling of surgical fluid waste. BioDrain's STREAMWAY System fully automates the collection, measurement and disposal of surgical fluids and is designed to result in: 1) reducing overhead costs to hospitals and surgical centers, 2) improving Occupational State and Health Association (OSHA) and other regulatory compliance agencies' safety concerns, and 3) streamlining the efficiency and reducing the operating costs of the operating room.

    BioDrain's STREAMWAY System is eco-friendly as it contributes to cleaning up the environment. Currently, approximately 50 million bloody, potentially disease infected canisters go to landfills annually in the United States. These tainted canisters can remain in landfills for years to come. With the installation of BioDrain's STREAMWAY System, the number of canisters can be significantly reduced. BioDrain Medical, Inc.'s STREAMWAY System is designed to make the operating room and our environment safer, cleaner, and better. BioDrain products are currently being represented by independent professional sales representatives that cater to the needs of hospitals and ambulatory surgical centers across the country. For additional information, please visit:

    Forward-looking Statements
    Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include, among other things, inability to raise sufficient additional capital to operate our business; unexpected costs and operating deficits, and lower than expected sales and revenues, if any; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; and inability to attract or retain qualified senior management personnel, including sales and  marketing personnel;our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission, which are available for review at This is not a solicitation to buy or sell securities and does not purport to be an analysis of the company's financial position. See the Company's most recent Annual Report on Form 10-K, as amended, and subsequent reports and other filings at

    Public Relations Contact:
    Samantha Wolf
    KCSA Strategic Communications

    Investor Relations Contacts:
    Phil Carlson / Josh Dver
    KCSA Strategic Communications
    212-896-1233 / 212-896-1239  BIODRAIN MEDICAL, INC. CONDENSED STATEMENTS OF OPERATIONS (USD $)3 Months EndedMar. 31, 2013Mar. 31, 2012Revenue$ 127,727

    $ 22,635Cost of Goods Sold41,604

    13,806Gross Margin86,123

    8,829General and administrative expenses1,823,082

    565,721Operations expense204,467

    69,737Sales and marketing expense83,969

    31,900Interest expense95,552

    55,488Loss (gain) on valuation of equity-linked financial instruments(19,422)

    (650)Total expense2,187,648

    722,196Net loss available to common shareholders$ (2,101,525)

    $ (713,367)Loss per common share - basic and diluted (in dollars per share)$ (0.02)

    $ (0.02)Weighted average shares used in computation - basic and diluted (in shares)107,824,939



    $ 372,854

    $ 13,139Accounts Receivable, net of Allowance for Doubtful Accounts of $4,073 in 2013

    and 2012.




    145,209Prepaid Expense and other assets


    27,409Total Current Assets667,022

    225,468Fixed Assets, net


    3,521Intangibles, net


    140,588Total Assets810,820

    369,577LIABILITIES AND STOCKHOLDERS' DEFICITCurrent portion of convertible debt, net of discounts of $77,644 and $21,138


    1,081,187Convertible Notes Payable - Related Party


    0Accounts payable


    733,595Accrued expenses


    1,599,519Deferred Revenue


    0Total Current Liabilities3,007,826

    3,414,301Long-term convertible debt


    89,300Accrued Expenses


    0Liability for equity-linked financial instruments


    169,179Stockholders' Deficit:Common stock, $.01 par value, 300,000,000 authorized, 120,303,418 and

    104,247,228 outstanding


    1,042,473Additional paid-in capital


    14,945,435Deficit accumulated during development stage


    (19,291,111)Total Stockholders' Deficit(2,844,665)

    (3,303,203)Total Liabilities and Stockholders' Deficit$ 810,820

    $ 369,577 

    SOURCE BioDrain Medical, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. BioDrain Medical Exhibits at National Registered Nurses Conference
    2. BioDrain Medical Retains KCSA Strategic Communications as Corporate Communications Counsel
    3. BioDrain Medical Inc. Signs Additional Independent Distribution Agreements, Strengthening Nationwide Presence
    4. BioDrain Medical, Inc. Implements Initiatives to Position Itself for Sustained Growth
    5. International Isotopes Inc. Announces First Quarter 2013 Financial Results
    6. Array BioPharma Announces Clinical Data Presentations At The 2013 ASCO Annual Meeting
    7. Concord Medical Announces the Signing of US$50 Million IFC Loan Agreement
    8. The Law Offices of Marc S. Henzel Announces Class Action Lawsuit Against Aveo Pharmaceuticals, Inc. and Certain Officers -- (Nasdaq: AVEO) was filed on behalf of stockholders
    9. Heska Announces Financial Results for the First Quarter of Fiscal 2013
    10. DEACOM ERP Announces MRO Module for Process and Mixed Mode Manufacturing Companies
    11. Natural Alternatives International, Inc. Announces Fiscal 2013 Q3 and YTD Results
    Post Your Comments:
    (Date:4/20/2017)... Research and Markets has announced the addition of ... By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, ... to their offering. ... The Latin American pharmaceutical contract manufacturing services market is anticipated ... drug registration cost in Latin American countries and continuous economic ...
    (Date:4/19/2017)... , April 19, 2017 Cardiology devices segment ... projected period The Cardiology Devices segment is likely ... US$ 15 Mn in 2018 over 2017. By the end ... market valuation close to US$ 700 Mn, expanding at a ... segment dominated the Asia Pacific reprocessed ...
    (Date:4/19/2017)...  IRIDEX Corporation (Nasdaq: IRIX ) today ... first quarter 2017 after the close of trading on ... host a corresponding conference call beginning at 2:30 p.m. ... in listening to the conference call may do so ... 326-3030 for international callers, using conference ID: 92158987.  A ...
    Breaking Medicine Technology:
    (Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... Brady ... announced that its B-595 and B-7569 vinyl label materials received ... and warning labels are tested to remain intact and legible, for use on chemical ...
    (Date:4/21/2017)... Portland, Maine (PRWEB) , ... April 21, 2017 ... ... agency, today announced it’s been named Agency of Record (AOR) for Theravent, ... reduce or eliminate snoring. Theravent’s parent company, Foundation Consumer Healthcare, is now working ...
    (Date:4/21/2017)... ... April 21, 2017 , ... ... exciting new partnership with the highly regarded and well renowned Asian distributor, Discovery ... myTAP & myTAP PAP Nasal Pillow Mask, and will stabilize and strengthen Airway’s ...
    (Date:4/21/2017)... ... April 21, 2017 , ... BrightStar Care Salt Lake City, a home care ... Utah (APCUT) and has appointed Rex Wheeler as its new Director of Business Development. ... agency and our ability to provide quality care to the community,” said Tammara Brown, ...
    (Date:4/21/2017)... ... April 21, 2017 , ... Federal mandate, fines, controversy, ... between the Obamacare program that most Republicans love to hate and Texas Agriculture ... kill hogs. , Like Obamacare, the Miller program centers upon a federal ...
    Breaking Medicine News(10 mins):